32863-33-5

Basic information

• Product Name: 1,2,3-BENZOXADIAZOLE-5-CARBALDEHYDE
• Synonyms: 2,1,3-BENZOXADIAZOLE-5-CARBOXALDEHYDE;2,1,3-BENZOXADIAZOLE-5-CARBALDEHYDE;1,2,3-BENZOXADIAZOLE-5-CARBALDEHYDE;CHEMBRDG-BB 4003957;BUTTPARK 154\50-77;2,1,3-Benzoxadiazole-5-carboxaldehyde (9CI);2,1,3-benzoxadiazole-5-carbaldehyde(SALTDATA: FREE);2,1,3-Benzoxadiazole-5-carboxaldehyde 97%
• CAS NO: 32863-33-5
• Molecular Formula: C₇H₄N₂O₂
• Molecular Weight: 148.12
• Product Categories: ALDEHYDE
• Mol File: 32863-33-5.mol
• Article Data: 9

Chemical Properties

• Melting Point: 58 °C
• Boiling Point: 277.3 °C at 760 mmHg
• Flash Point: 121.5 °C
• Appearance: /
• Density: 1.417 g/cm³
• Vapor Pressure: 0.00457mmHg at 25°C
• Refractive Index: 1.676
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1,2,3-BENZOXADIAZOLE-5-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3-BENZOXADIAZOLE-5-CARBALDEHYDE(32863-33-5)
• EPA Substance Registry System: 1,2,3-BENZOXADIAZOLE-5-CARBALDEHYDE(32863-33-5)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 24/25
• HazardClass: IRRITANT
• Hazardous Substances Data: 32863-33-5(Hazardous Substances Data)

Usage

General Description

1,2,3-Benzoxadiazole-5-carbaldehyde is a chemical compound with the molecular formula C8H5NO2. It is a derivative of benzoxadiazole and is commonly used in the synthesis of organic compounds. This chemical is often utilized as a fluorescent probe for the detection of various biological targets, including DNA and proteins. It is known for its unique photophysical properties, such as high fluorescence quantum yield and high photostability, making it valuable in fluorescent labeling and imaging applications. Additionally, 1,2,3-Benzoxadiazole-5-carbaldehyde has potential applications in the development of new materials for optoelectronic devices and sensors due to its optoelectronic properties.

InChI:InChI=1/C7H4N2O2/c10-4-5-1-2-6-7(3-5)9-11-8-6/h1-4H

Upstream product

• 36389-14-7 5-Dibromomethylbenzofurazan 
• 19164-41-1 5-methylbenzofuroxan 
• 57948-15-9 5-formylbenzo[1,2-c]1,2,5-oxadiazole N¹-oxide 
• 42564-51-2 4-fluoro-3-nitrobenzaldehyde 
• 459-57-4 4-fluorobenzaldehyde 
• 19155-93-2 4-azido-3-nitrobenzaldehyde 
• 16588-34-4 4-chloro-3-nitro-benzaldehyde 
• 19164-42-2 5-formylbenzo[c][1,2,5]oxadiazole 1-oxide 
• 104-88-1 4-chlorobenzaldehyde 
• 20304-86-3 5-methyl-benzo[1,2,5]oxadiazole 
• 32863-31-3 5-(bromomethyl)benzofurazan 
• 59660-56-9 benzo[c][1,2,5]oxadiazol-5-ylmethanol 

Downstream Products

• 59660-56-9 benzo[c][1,2,5]oxadiazol-5-ylmethanol 
• 32863-31-3 5-(bromomethyl)benzofurazan 
• 1367578-50-4 5-(benzo[c][1,2,5]oxadiazol-5-ylmethylene)-3-benzyl-2-thioxothiazolidin-4-one 
• 391610-40-5 6-(Benzofurazan-5-yl)-1,6-dihydro-2-methoxy-5-methoxycarbonyl-4-methyl-1-[(4-nitrophenyloxy)carbonyl]pyrimidine 
• 116904-74-6 2-[1-Benzo[1,2,5]oxadiazol-5-yl-meth-(Z)-ylidene]-3-oxo-butyric acid methyl ester 

Relevant articles and documents

Piperidine compound and preparation method and medical application thereof

The invention discloses a piperidine compound shown as a formula (I) and a preparation method and medical application thereof, and particularly relates to a piperidine USP7 inhibitor compound or pharmaceutically acceptable salt or ester or solvate thereof and a preparation method and application of the piperidine USP7 inhibitor compound or pharmaceutically acceptable salt or ester or solvate thereof. The compound provided by the invention can inhibit the activity of USP7 enzyme, has very good selectivity and druggability, and can be used for preparing medicines for preventing or treating tumor diseases or virus infectious diseases.

Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity

A series of phenoxybutanoic acid derivatives were synthesized and tested for their antagonistic activity on the contraction of the rat thoracic aortic ring induced by endothelin-1. Preliminary screening results showed that 6e and 6g with benzoheterocycles demonstrated significant antagonistic activities when compared to the reference compound BQ123. The results from additional assays for the binding affinity and selectivity for endothelin receptors showed that 6e was a selective ETA antagonist with a nanomolar IC50. Moreover, 6e was effective in relieving hypoxia-induced pulmonary arterial hypertension and right ventricular weight ratio. Therefore, 6e may have potential for further development as a therapeutic agent for the treatment of cardiovascular diseases.

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human α1Areceptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the α1Areceptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.